Targeting HSP90 in malignant gliomas: onalespib as a potential therapeutic
Glioblastoma (GBM) is the most common of all highgrade gliomas (HGGs). It accounts for almost 80% of all malignant primary neoplasms of the brain (1). It is a very aggressive tumor, with historical median survival rates of less than 2 years. Patients receiving standard of care following surgical resection, temozolomide (TMZ) plus radiation therapy, have a median survival of 14- 18 months, highlighting the need for developing novel therapeutic strategies to effectively target malignant gliomas while preserving quality of life (2). Malignant gliomas are characterized by cellular heterogeneity, are highly vascularized, and invasive, which influence their resistance to conventional treatments and poor clinical outcomes.